Before approving the new weight loss diet pills, Belviq(Lorcaserin) and Qsymia(Phentermine and Topiramate) in the middle of 2012, the US FDA has denied each and every diet pill that came before it for review for 13 years for one reason or the other while the countries waist lines have been expanding!
FDA needed a weight loss doctor on its panel that reviews new weight loss drugs!
The previous FDA panels that rejected many weight loss medications in the prior 10 years before this when no new weight loss medications were approved, reportedly did not have a single practicing bariatric physician on their panel.
However, that changed in early 2012 when they took a practicing bariatric medicine or obesity medicine specialist on their panel that reviews new weight loss medication applications (NDA). Not so surprisingly, within 6 months of having a bariatric physician on the panel of experts that look at these studies on new weight loss medications, two new weight loss medications, Belviq and Qsymia, were approved.
Information on weight loss medication Qsymia
The U.S. Food and Drug Administration approved the combination of Phentermine and Topiramate, marketed as Qsymia as an addition to a reduced-calorie diet and exercise for chronic weight management.
When was Qsymia FDA approved for weight loss?
On July 17th, 2012.
The U.S. Food and Drug Administration today approved Qsymia(phentermine and topiramate extended-release) as an addition to a reduced-calorie diet and exercise for chronic weight management.
Who can take Qsymia for weight loss?
The drug is approved to be used in adults with a body mass index (BMI) of thirty or larger (obese) or adults with a BMI of twenty seven or larger (overweight) that have a minimum of one weight-related condition like high vital sign (hypertension), lipid problems, diabetes, heart disease etc.
What are the active ingredients in the new diet pill, Qsymia?
Qsymia is a new combination of 2 FDA-approved medicines that are already on the market as generics – phentermine and topiramate, in associate extended-release formulation. Phentermine is indicated for short weight loss in overweight or corpulent adults WHO square measure physical exertion and ingestion a reduced calorie diet. Topiramate is indicated to treat bound forms of seizures in people that have brain disorder and to stop head ache headaches.
Who should not take Qsymia?
Qsymia should not be used throughout gestation as a result of it will cause neural tube defects in foetus.
What are the results of safety and efficacy studies done on Qsymia?
The safety and efficacy of Qsymia were evaluated in 2 randomised, placebo-controlled trials that enclosed some three,700 corpulent and overweight patients with and while not important weight-related conditions treated for one year. All patients received style modification that consisted of a reduced calorie diet and regular physical activity.
What is the suggested daily dose of Qsymia?
The suggested starting daily dose of Qsymia contains seven and half milligrams of phentermine and forty six mg of topiramate extended-release. Qsymia is additionally obtainable at a better dose (15 mg phentermine and ninety two mg of topiramate extended-release) for choose patients.
How much weight loss was seen in research studies on Qsymia?
Results from the 2 trials show that once one year of treatment with the suggested and highest daily dose of Qsymia, patients had a median weight loss of 6.7 % and eight point nine percent, respectively over treatment with placebo. some sixty two % and sixty nine % of patients lost a minimum of 5 % of their weight with the suggested dose and highest dose of Qsymia, respectively, compared with concerning twenty % of patients treated with placebo.
How long should one try Qsymia?
After 4 months from start or 3 months after full titration, if you have not lost at least 5 percent of your body weight, it is unlikely that you would succeed in losing weight with Qsymia and therefore, should be discontinued.
Patients WHO failed to lose a minimum of 3 % of their weight by week twelve of treatment with Qsymia were unlikely to realize and sustain weight loss with continued treatment at this dose. Therefore, response to medical care with the suggested daily dose of Qsymia ought to be evaluated by twelve weeks to work out, supported the number of weight loss, whether or not to discontinue Qsymia or increase to the upper dose. If once twelve weeks on the upper dose of Qsymia, a patient doesn’t lose a minimum of 5 % of weight, then Qsymia ought to be interrupted, as these patients square measure unlikely to realize clinically meaty weight loss with continued treatment.
Who should not take Qsymia?
Qsymia should not be utilized in patients with certain types of eye diseases such as narrow angle glaucoma. Qsymia will increase pulse; this drug’s impact on heart rate in patients at high risk for attack or stroke isn’t identified. Therefore, the employment of Qsymia in patients with recent (within the last six months) or unstable cardiopathy or stroke isn’t suggested. Regular observance of pulse is suggested for all patients taking Qsymia, particularly once beginning Qsymia or increasing the dose.
What are the REMS programs placed on Qsymia?
The bureau(FDA) approved Qsymia with a Risk analysis and Mitigation Strategy (REMS), that consists of a drugs Guide advising patients concerning necessary safety data and parts to assure safe use that embrace prescriber.
The most common side effects of Qsymia square measure tingling of hands and feet (paresthesia), dizziness, altered sense datum, insomnia, constipation, and xerostomia.
Who makes Qsymia in the United States?
Qsymia is marketed by Vivus.
Is there a generic available for Qsymia?
No. Although there is no generic for Qsymia, the off label use of generic combination of Phentermine and Topiramate in somewhat similar dosages gives similar weight loss results for a huge cost saving.
What is the Cost of Qsymia?
Costing about $190-200.00 per month, the brand name Qsymia might be a bit expensive for some and the generic Phentermine and Topiramate in somewhat similar dosing can be more economically obtained as these might be included in the biweekly program cost of $50.00 at most W8MD medical weight loss center locations.
How about Coupons for Qsymia?
The manufacturer of Qsymia, Vivus Inc. might offer Coupons from time to time.
Free To Start Offer of Qsymia for two weeks at the starting dose of 3.75/23 mg
The manufacturer offers a free two week trial of Qsymia and is made available for your convenience at most W8MD medical weight loss center locations.
Limitations and exclusions might apply for this free trial offer. According to the manufacturer, claims for any product dispensed through the Free to Start Offer may not be submitted to any public payer (for example, Medicaid, Medicare, Tricare, VA, Department of Defense, Indian Health Service) for reimbursement. The free trial offer is valid only for the first 14 days of Qsymia 3.75 mg/23 mg. Limit 1 free trial per patient. No purchase is necessary.
Monthly Savings Offer of Qsymia with Coupon
The manufacturer of Qsymia also offers a Coupon for non-government insurances that can save up to $75 on your 30 day prescription of Qsymia (12 fills, all doses). This means, you will approximately $125.00 a month instead of the regular price of about $200.00 as this Coupon is valid for $75.00 savings on Qsymia with a valid prescription and only if you do not have a government issued insurance such as Medicare, Medicaid, Tricare, VA etc.
The discount offer is available on up to twelve (12) prescription fills for 30 days each of Qsymia. Not available to individuals enrolled in any government-funded insurance program that covers prescription drugs (for example, Medicaid, Medicare, Tricare, VA, Department of Defense, Indian Health Service) or where prohibited by law. Eligible patients will have $75 deducted from the pre-tax price per prescription. Insured patients pay first $60 of copay and then monthly savings offer covers up to $75 of remaining.
Where to get coupons for Qsymia?
Most W8MD medical weight loss centers offer Coupons Qsymia, Belviq, Contrave, Saxenda etc. for your convenience
Which weight loss medications Qsymia or Belviq right for me?
Our experienced weight loss physicians at W8MD medical weight loss centers of America can discuss which weight loss medication or diet pill is right for you based on your medical condition, insurance, personal preferences and can prescribe Belviq, Qsymia, Contrave, Saxenda, Adipex, Bontril, HCG or any other weight loss medication or supplement when medically appropriate in addition to a reduced calorie diet and increased physical activity!
Other weight loss drugs to consider and compare Qsymia with:
- Contrave (Bupropion and Naltrexone) – Brand new weight loss medication
- The latest weight loss drug FDA approved in December of 2014, Saxenda
- Phentermine and Topiramate (Qsymia) – New diet pill! (Phentermine and Topiramate is one of the most popular and most effectiveweight loss medications) for fast weight loss!
- Lorcaserin (Belviq) – New weight loss medication FDA approved in June of 2012.
- Phentermine (Adipex)
- Topiramate (Topamax)
- Phendimetrazine (Bontril)
- Diethylpropion (Tenuate)
- Xenical and others
- Of all these weight loss medications, which is the most effective?
- Which diet pill is the safest for losing weight for me?
- What is the most cost effective weight loss pill?
- Which doctor should I consult with in order to get all my questions answered?
Since most W8MD medical weight loss centers locations accept most health insurances for physician weight loss visits, there has never been a better and more cost effective, cheaper way to lose weight! In fact, most non-medical weight loss programs such as Jenny Craig cost more than what most W8MD medical weight loss programs cost to lose weight!
New Weight loss medications Qsymia and Belviq right for me?
Call us today for a consultation to determine whether Qsymia, Belviq, Contrave, Saxenda, Adipex, Bontril or any other medication is right for you to suppress appetite in addition to diet and exercise.
Philadelphia Weight Loss Center: 1718, Welsh Rd, Philadelphia, PA, 19115 Ph: 1-215-676-2334 & 1-800-W8MD-007
King Of Prussia Weight Loss Center: 987 Old Eagle School Rd, Ste 712, Wayne, PA, 19087 Ph: 215-676-2334 and 1-800-986-3007
NYC Insurance Weight Loss Center: 2003, Bath Avenue, Brooklyn, NY, 11214 Ph: 1-718-946-5500 & 718-946-5501